Shares of Canadian medical marijuana producer and distributor Aurora Cannabis Inc. (ACB - Get Report) reversed course on Tuesday, ending the day down some 4% after the company announced that its fiscal second-quarter revenue likely will ring in strong.
Shares of the Edmonton-based producer of medical and recreational marijuana initially rose to $5.30 in early trading on the New York Stock Exchange after ending the day Monday up 4 cents at $5.26. However, the shares reversed course, ending the trading day Tuesday down 4.43%, or 31 cents, at $6.68.
In a statement released Tuesday, the company said it was now anticipating fiscal second-quarter revenue of between C$50 million and C$55 million, compared to C$11.7 million for the prior-year quarter and compared to C$29.7 million for its fiscal first quarter ended Sept. 30.
Revenue growth for the quarter was driven by the Company's strong position in the adult consumer use market in Canada, continued shipments of medical cannabis to Aurora's expanding base of about 71,000 patients in Canada, and relatively stable, supply restricted shipments to its growing international markets, the company said.
"Going forward, we see sustained strong demand from the adult usage market, as evidenced by public statements from the Canadian provinces, as well as strong patient-driven demand for medical cannabis in Canada and abroad," said CEO Terry Booth. "These factors, together with our focus on disciplined management of operating expenses, and our growing portfolio of higher margin products, put us in a position to rapidly achieve positive EBITDA within the next two quarters."
Achieving earnings before income, taxes and amortization - an efficiency measurement that calculates a company's operational profitability by including equipment costs and excluding financing costs - is a key factor that many marijuana companies will need to achieve this year to demonstrate their ability to generate longer-term profits said Charles Taerk, CEO of Toronto-based Faircourt Asset Management, sub-advisor to the Ninepoint Alternative Health Fund which invests in global alternative health companies.
"Overall, we believe that 2019 will be a positive year for the industry," Taerk said in a 2019 outlook note to clients. "However, companies in the sector are going to need to execute and show improved financial performance. We believe that there will be significant differences in stock performance based on important metrics like sales price, market share, EBITDA, and for those pursuing it, results from international sales."